Aclarion, Inc. (NASDAQ: ACON)

Sector: Healthcare Industry: Health Information Services CIK: 0001635077
Market Cap 19,202.40
P/B 0.00
P/E 0.00
P/S 0.28
ROIC (Qtr) -51.45
Div Yield % 0.00
Rev 1y % (Qtr) 31.48
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00

About

Aclarion, Inc., with its ticker symbol ACON, is a healthcare technology company that specializes in leveraging Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company operates in the healthcare industry, specifically addressing the low back and neck pain market in the United States, which is currently the most costly healthcare condition in the country. Aclarion's primary business activities revolve around the development and commercialization of its proprietary technology that uses MRS to identify...

Read more

Price action

Investment thesis

Bull case

  • Tangible assets of 11.92M provide robust 28.02x coverage of other current liabilities 425388, indicating strong asset backing.
  • Cash reserves of 11.37M provide robust 16.24x coverage of current liabilities 699747, indicating strong short-term solvency.
  • Strong cash position of 11.37M provides 26.72x coverage of other current liabilities 425388, indicating excellent liquidity.
  • Cash position of 11.37M represents healthy 1.01x of working capital 11.20M, demonstrating strong operational liquidity.
  • Tangible assets of 11.92M provide robust 17.03x coverage of current liabilities 699747, showing strong asset backing.

Bear case

  • Investment activities of (223158) provide weak support for R&D spending of 1.02M, which is -0.22x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (6.46M) shows concerning coverage of stock compensation expenses of 157621, with a -40.98 ratio indicating potential earnings quality issues.
  • Free cash flow of (6.47M) provides weak coverage of capital expenditures of 12917, with a -501.09 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (7.33M) show weak coverage of depreciation charges of 218339, with a -33.59 ratio indicating high capital intensity and potential reinvestment needs.
  • High financing cash flow of 16.73M relative to working capital of 11.20M, which is 1.49x suggests concerning dependence on external funding for operational needs.

Peer comparison

Companies in the Health Information Services
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TEM Tempus AI, Inc. 45.63 Bn -223.83 41.29 1.34 Bn
2 GEHC GE HealthCare Technologies Inc. 38.75 Bn 19.85 2.19 10.28 Bn
3 VEEV Veeva Systems Inc 37.30 Bn 43.36 12.11 0.09 Bn
4 DOCS Doximity, Inc. 7.81 Bn 30.87 12.57 0.01 Bn
5 BTSG BrightSpring Health Services, Inc. 7.70 Bn 59.42 0.62 2.70 Bn
6 HQY Healthequity, Inc. 7.32 Bn 38.14 5.67 1.03 Bn
7 WAY Waystar Holding Corp. 5.00 Bn 44.97 4.81 1.25 Bn
8 PRVA Privia Health Group, Inc. 2.79 Bn 153.67 1.37 0.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets -0.97 2.77
EV to Cash from Ops. EV/CFO 1.99 -10.86
EV to Debt EV to Debt 0.00 161.93
EV to EBIT EV/EBIT 1.75 -106.48
EV to EBITDA EV/EBITDA 1.93 4.22
EV to Free Cash Flow [EV/FCF] EV/FCF 1.98 7.46
EV to Market Cap EV to Market Cap -668.22 -14.93
EV to Revenue EV/Rev -190.14 1.76
Price to Book Value [P/B] P/B 0.00 10.57
Price to Earnings [P/E] P/E 0.00 147.14
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) -136.27 -8.65
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 5.00
Dividend per Basic Share Div per Share (Qtr) 0.00 0.04
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 4.57
Interest Coverage Int. cover (Qtr) -27,061.95 -584.72
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 -24.09
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 759.72 172.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -1.05
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -37.34 -17.73
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -42.94 39.85
EBIT Growth (1y) % EBIT 1y % (Qtr) -37.34 -38.83
EBT Growth (1y) % EBT 1y % (Qtr) -16.99 -4.52
EPS Growth (1y) % EPS 1y % (Qtr) 92.82 2.60
FCF Growth (1y) % FCF 1y % (Qtr) -27.35 -48.57
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 84.56 5.49
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.01 0.66
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.03
Cash Ratio Cash Ratio (Qtr) 16.24 1.87
Current Ratio Curr Ratio (Qtr) 17.01 3.27
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 -0.43
Interest Cover Ratio Int Coverage (Qtr) -27,061.95 -584.72
Times Interest Earned Times Interest Earned (Qtr) -27,061.95 -584.72
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -10,543.90 -435.80
EBIT Margin % EBIT Margin % (Qtr) -10,867.45 -464.70
EBT Margin % EBT Margin % (Qtr) -10,867.85 -461.74
Gross Margin % Gross Margin % (Qtr) -7.80 44.03
Net Profit Margin % Net Margin % (Qtr) -10,948.20 -468.01